Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Omar, Nadeem"'
Autor:
Charlotte Pawlyn, Fredrik H. Schjesvold, David A. Cairns, L. J. Wei, Faith Davies, Omar Nadeem, Haifaa Abdulhaq, Maria-Victoria Mateos, Jacob Laubach, Katja Weisel, Heinz Ludwig, S. Vincent Rajkumar, Pieter Sonneveld, Graham Jackson, Gareth Morgan, Paul G. Richardson
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Measurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is increasingly challenging to use OS as the primary e
Externí odkaz:
https://doaj.org/article/186d300a7c3d4b47adaec4bd25b20ac5
Autor:
Xiang Zhou, Patrick Costello, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Max Topp, Hartmut Goldschmidt, Hermann Einsele, Nikhil C Munshi, Marc S Raab, Joseph Kauer, Thomas Hielscher, Niels Weinhold, Mirco J Friedrich, Sandra Sauer, Leo Rasche, Thomas Luft, Jan H Frenking, Vivien Wagner, Elias K Mai, Christian S Michel, Marina Hajiyianni, Iris Breitkreutz, Omar Nadeem, Adam S Sperling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine re
Externí odkaz:
https://doaj.org/article/8940433ced884d68a993840e8bd1f4cb
Autor:
Aimaz Afrough, Hamza Hashmi, Doris K. Hansen, Surbhi Sidana, Chul Ahn, Lauren C. Peres, Danai Dima, Ciara L. Freeman, Omar Castaneda Puglianini, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Leyla Shune, Joseph P. McGuirk, Gary Simmons, Douglas W. Sborov, James A. Davis, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher J. Ferreri, Mahmoud R. Gaballa, Scott Goldsmith, Omar Nadeem, Shonali Midha, Charlotte B. Wagner, Frederick L. Locke, Krina K. Patel, Jack Khouri, Larry D. Anderson, Yi Lin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/3e7b6b54104143d6819770a8ea596373
Autor:
Benjamin Ackerman, Ryan W. Gan, Craig S. Meyer, Jocelyn R. Wang, Youyi Zhang, Jennifer Hayden, Grace Mahoney, Jennifer L. Lund, Janick Weberpals, Sebastian Schneeweiss, James Roose, Juned Siddique, Omar Nadeem, Smith Giri, Til Stürmer, Sikander Ailawadhi, Ashita S. Batavia, Khaled Sarsour
Publikováno v:
Frontiers in Drug Safety and Regulation, Vol 4 (2024)
Introduction: While randomized controlled trials remain the reference standard for evaluating treatment efficacy, there is an increased interest in the use of external control arms (ECA), namely in oncology, using real-world data (RWD). Challenges re
Externí odkaz:
https://doaj.org/article/c00455226d6749b884e3043112d1c680
Autor:
Maho Terashita, Umut Selamet, Shonali Midha, Omar Nadeem, Jacob Laubach, Helmut G. Rennke, Naoka Murakami
Publikováno v:
Kidney International Reports, Vol 8, Iss 12, Pp 2765-2777 (2023)
Introduction: Monoclonal gammopathy of renal significance (MGRS) is characterized by monoclonal immunoglobulin deposition in kidneys. However, monoclonal immunoglobulin and responsible clone(s) are not always detectable. Treatment response and kidney
Externí odkaz:
https://doaj.org/article/0cd6ba13dbd94655b120bb5a4b389679
Autor:
David J Lee, Elizabeth K O'Donnell, Noopur Raje, Cristina Panaroni, Robert Redd, Jennifer Ligibel, Dorothy D Sears, Omar Nadeem, Irene M Ghobrial, Catherine R Marinac
Publikováno v:
JMIR Research Protocols, Vol 13, p e51368 (2024)
BackgroundObesity is an established, modifiable risk factor of multiple myeloma (MM); yet, no lifestyle interventions are routinely recommended for patients with overweight or obesity with MM precursor conditions. Prolonged nightly fasting is a simpl
Externí odkaz:
https://doaj.org/article/2337909fc38a47099368b1c9f66691d9
Autor:
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 792-810 (2023)
Abstract Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nu
Externí odkaz:
https://doaj.org/article/df6d5d22d8aa4c3088dccaac48019fd0
Autor:
Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed cl
Externí odkaz:
https://doaj.org/article/ba30b147cb5a40229e9257f0ed0c5838
Autor:
Monique A. Hartley-Brown, Clifton C. Mo, Omar Nadeem, Shonali Midha, Jacob P. Laubach, Paul G. Richardson
Publikováno v:
Cancers, Vol 16, Iss 6, p 1166 (2024)
Mezigomide is an oral cereblon E3 ligase modulator (CELMoD) that is under clinical investigation in patients with relapsed/refractory (RR) multiple myeloma (MM). Like other CELMoD compounds, mezigdomide acts by altering the conformation of cereblon w
Externí odkaz:
https://doaj.org/article/34f7fe73757a4294b4137883c3ca5d23
Autor:
Omar Nadeem, Sikander Ailawadhi, Jack Khouri, Louis Williams, Donna Catamero, Kathryn Maples, Jesús Berdeja
Publikováno v:
Cancers, Vol 16, Iss 5, p 1023 (2024)
Multi-agent regimens incorporating immunomodulatory (IMiD®) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved surviva
Externí odkaz:
https://doaj.org/article/3a0a46aa916e429d8166e8d35d776112